2023 World Conference on Lung Cancer (Posters)-P2.08. A Phase II Study of Subcutaneous (SC) Atezolizumab in NSCLC Patients Using a Decentralized Clinical Trial Model

P2.08. A Phase II Study of Subcutaneous (SC) Atezolizumab in NSCLC Patients Using a Decentralized Clinical Trial Model - PDF(Abstract)

Back to course

Pdf Summary

This document describes a Phase II study that aims to establish the feasibility of administering checkpoint inhibitor therapy at home using a remote clinical trial model. The study focuses on subcutaneous (SC) atezolizumab in patients with non-small cell lung cancer. The COVID-19 pandemic has disrupted oncology care, including access to clinical trials. The study proposes a decentralized trial model that can be accessed via telemedicine, allowing for treatment and monitoring to be done locally. The use of telemedicine has proven to be a convenient and cost-effective option for cancer patients. However, this model has not been tested for clinical trials.<br /><br />The study will enroll 37 patients and employ remote consenting and physician visits conducted via telemedicine. Patient data will be captured and transmitted using a smartphone application. The study will combine smartphone-based activity tracking, home vital sign monitoring, and patient-reported outcomes. The safety and feasibility of home administration of SC atezolizumab will be measured. The study is supported by a research grant to USC/Norris Comprehensive Cancer Center from Genentech.<br /><br />The use of distributed clinical trials and remote patient care has become more prevalent due to the COVID-19 pandemic. This study aims to adapt to these changes and explore the potential benefits of administering checkpoint inhibitor therapy at home. Atezolizumab, a promising treatment option for various tumor types, is being studied in its subcutaneous formulation to facilitate care at home. The results of this study could have implications for improving patient access to clinical trials and cancer care in general.

Asset Subtitle

Jorge Nieva

Meta Tag

Speaker Jorge Nieva

Topic Metastatic NSCLC: Immunotherapy - TIPs

Keywords

Phase II study

checkpoint inhibitor therapy

home administration

remote clinical trial model

subcutaneous atezolizumab

non-small cell lung cancer

decentralized trial model

telemedicine

cancer patients

distributed clinical trials